Shape-shifting serpins - advantages of a mobile mechanism

Trends in Biochemical Sciences

Volumn 31, Issue 8, 2006, Pages 427-435

  Huntington, James A ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 MACROGLOBULIN; ANTITHROMBIN; ENZYME; SERINE PROTEINASE INHIBITOR;

ALPHA HELIX; BETA CHAIN; CARBOXY TERMINAL SEQUENCE; CONFORMATIONAL TRANSITION; COVALENT BOND; CRYSTAL STRUCTURE; ENZYME CONFORMATION; ENZYME DEGRADATION; ENZYME MECHANISM; ENZYME STABILITY; ENZYME STRUCTURE; MICHAELIS CONSTANT; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL; PROTEIN FOLDING; REVIEW; STRUCTURE ANALYSIS; THERMODYNAMICS; THERMOSTABILITY;

ANIMALS; ANTITHROMBINS; HEPARIN COFACTOR II; HUMANS; KINETICS; MODELS, MOLECULAR; PROTEIN CONFORMATION; SERINE ENDOPEPTIDASES; SERPINS;

EID: 33746503823     PISSN: 09680004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibs.2006.06.005     Document Type: Review

References (76)

1. Carrell R.W., and Travis J. α-1-Antitrypsin and the serpins: variation and countervariation. Trends Biochem. Sci. 10 (1985) 20-24
2. Hunt L.T., and Dayhoff M.O. A surprising new protein superfamily containing ovalbumin, antithrombin-III, and α1-proteinase inhibitor. Biochem. Biophys. Res. Commun. 95 (1980) 864-871
3. Silverman G.A., et al. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions and a revised nomenclature. J. Biol. Chem. 276 (2001) 33293-33296
4. Irving J.A., et al. Computational analysis of evolution and conservation in a protein superfamily. Methods 32 (2004) 73-92
5. Gettins P.G. Serpin structure, mechanism, and function. Chem. Rev. 102 (2002) 4751-4804
6. Van Gent D., et al. Serpins: structure, function and molecular evolution. Int. J. Biochem. Cell Biol. 35 (2003) 1536-1547
7. Gettins P.G.W., et al. Serpins: Structure, Function and Biology (1996), R.G. Landes Co.
8. Lundgard R., and Svensson B. A 39 kD barley seed protein of the serpin superfamily inhibits α-chymotrypsin. Carlsberg Res. Commun. 54 (1989) 173-180
9. Perrocheau L., et al. Probing heat-stable water-soluble proteins from barley to malt and beer. Proteomics 5 (2005) 2849-2858
10. Rawlings N.D., et al. Evolutionary families of peptidase inhibitors. Biochem. J. 378 (2004) 705-716
11. Whisstock, J.C. et al. (2005) Serpins 2005 - fun between the β-sheets. Meeting report based upon presentations made at the 4th International Symposium on Serpin Structure, Function and Biology (Cairns, Australia). FEBS J. 272, 4868-4873
12. Elliott P.R., et al. Wild-type α1-antitrypsin is in the canonical inhibitory conformation. J. Mol. Biol. 275 (1998) 419-425
13. Schechter I., and Berger A. On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 27 (1967) 157-162
14. Kaslik G., et al. Effects of serpin binding on the target proteinase: global stabilization, localized increased structural flexibility, and conserved hydrogen bonding at the active site. Biochemistry 36 (1997) 5455-5464
15. Sancho E., et al. Conformational studies on plasminogen activator inhibitor (PAI-1) in active, latent, substrate, and cleaved forms. Biochemistry 34 (1995) 1064-1069
16. Mushunje A., et al. Latent antithrombin and its detection, formation and turnover in the circulation. J. Thromb. Haemost. 2 (2004) 2170-2177
17. Im H., et al. Bypassing the kinetic trap of serpin protein folding by loop extension. Protein Sci. 9 (2000) 1497-1502
18. Olson S.T., et al. Role of the catalytic serine in the interactions of serine proteinases with protein inhibitors of the serpin family. Contribution of a covalent interaction to the binding energy of serpin-proteinase complexes. J. Biol. Chem. 270 (1995) 30007-30017
19. Wright H.T., and Scarsdale J.N. Structural basis for serpin inhibitor activity. Proteins 22 (1995) 210-225
20. Stratikos E., and Gettins P.G. Formation of the covalent serpin-proteinase complex involves translocation of the proteinase by more than 70 Å and full insertion of the reactive center loop into β-sheet A. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 4808-4813
21. Stratikos E., and Gettins P.G. Major proteinase movement upon stable serpin-proteinase complex formation. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 453-458
22. Stratikos E., and Gettins P.G. Mapping the serpin-proteinase complex using single cysteine variants of α1-proteinase inhibitor Pittsburgh. J. Biol. Chem. 273 (1998) 15582-15589
23. Huntington J.A., et al. Structure of a serpin-protease complex shows inhibition by deformation. Nature 407 (2000) 923-926
24. Loebermann H., et al. Human α1-proteinase inhibitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function. J. Mol. Biol. 177 (1984) 531-557
25. Ye S., et al. The structure of a Michaelis serpin-protease complex. Nat. Struct. Biol. 8 (2001) 979-983
26. Dementiev A., et al. Canonical inhibitor-like interactions explain reactivity of α1-proteinase inhibitor Pittsburgh and antithrombin with proteinases. J. Biol. Chem. 278 (2003) 37881-37887
27. Olson S.T., et al. Resolution of Michaelis complex, acylation, and conformational change steps in the reactions of the serpin, plasminogen activator inhibitor-1, with tissue plasminogen activator and trypsin. Biochemistry 40 (2001) 11742-11756
28. Dementiev A., et al. Active site distortion is sufficient for proteinase inhibition by serpins: structure of the covalent complex of α1-proteinase inhibitor with porcine pancreatic elastase. J. Biol. Chem. 281 (2006) 3452-3457
29. Stavridi E.S., et al. Structural change in α-chymotrypsin induced by complexation with α1-antichymotrypsin as seen by enhanced sensitivity to proteolysis. Biochemistry 35 (1996) 10608-10615
30. Kaslik G., et al. Trypsin complexed with α1-proteinase inhibitor has an increased structural flexibility. FEBS Lett. 370 (1995) 179-183
31. Egelund R., et al. A serpin-induced extensive proteolytic susceptibility of urokinase-type plasminogen activator implicates distortion of the proteinase substrate-binding pocket and oxyanion hole in the serpin inhibitory mechanism. Eur. J. Biochem. 268 (2001) 673-685
32. Calugaru S.V., et al. The pH dependence of serpin-proteinase complex dissociation reveals a mechanism of complex stabilization involving inactive and active conformational states of the proteinase which are perturbable by calcium. J. Biol. Chem. 276 (2001) 32446-32455
33. Bock P.E., et al. Inactivation of thrombin by antithrombin is accompanied by inactivation of regulatory exosite I. J. Biol. Chem. 272 (1997) 19837-19845
34. Fredenburgh J.C., et al. Conformational changes in thrombin when complexed by serpins. J. Biol. Chem. 276 (2001) 44828-44834
35. 15N] NMR studies of the 69 kDa α1-proteinase inhibitor Pittsburgh-trypsin covalent complex. Biochemistry 40 (2001) 6284-6292
36. Amour A., et al. General considerations for proteolytic cascades. Biochem. Soc. Trans. 32 (2004) 15-16
37. Lowe G.D. Factor IX and thrombosis. Br. J. Haematol. 115 (2001) 507-513
38. Lu G., et al. Formation of factors IXa and Xa by the extrinsic pathway: differential regulation by tissue factor pathway inhibitor and antithrombin III. J. Biol. Chem. 279 (2004) 17241-17249
39. Bjork I., and Olson S.T. Antithrombin. A bloody important serpin. Adv. Exp. Med. Biol. 425 (1997) 17-33
40. Quinsey N.S., et al. Antithrombin: in control of coagulation. Int. J. Biochem. Cell Biol. 36 (2004) 386-389
41. Huntington J.A. Heparin activation of serpins. In: Garg H.G. (Ed). Chemistry and Biology of Heparin and Heparan Sulfate (2005), Elsevier 367-398
42. Carrell R.W., et al. Biological implications of a 3 Å structure of dimeric antithrombin. Structure 2 (1994) 257-270
43. Langdown J., et al. Allosteric activation of antithrombin critically depends upon hinge region extension. J. Biol. Chem. 279 (2004) 47288-47297
44. Petitou M., et al. 1976-1983, a critical period in the history of heparin: the discovery of the antithrombin binding site. Biochimie 85 (2003) 83-89
45. McCoy A.J., et al. Structure of β-antithrombin and the effect of glycosylation on antithrombin's heparin affinity and activity. J. Mol. Biol. 326 (2003) 823-833
46. Johnson D.J., and Huntington J.A. Crystal structure of antithrombin in a heparin-bound intermediate state. Biochemistry 42 (2003) 8712-8719
47. Jin L., et al. The anticoagulant activation of antithrombin by heparin. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 14683-14688
48. Dementiev A., et al. The ternary complex of antithrombin-anhydrothrombin-heparin reveals the basis of inhibitor specificity. Nat. Struct. Mol. Biol. 11 (2004) 863-867
49. Li W., et al. Structure of the antithrombin-thrombin-heparin ternary complex reveals the antithrombotic mechanism of heparin. Nat. Struct. Mol. Biol. 11 (2004) 857-862
50. Johnson D.J., et al. Antithrombin-S195A factor Xa-heparin structure reveals the allosteric mechanism of antithrombin activation. EMBO J. 25 (2006) 2029-2037
51. Yang L., et al. Heparin-activated antithrombin interacts with the autolysis loop of target coagulation proteases. Blood 104 (2004) 1753-1759
52. Izaguirre G., and Olson S.T. Residues Tyr253 and Glu255 in strand 3 of β-sheet C of antithrombin are key determinants of an exosite made accessible by heparin activation to promote rapid inhibition of factors Xa and IXa. J. Biol. Chem. 281 (2006) 13424-13432
53. Tollefsen D.M. Heparin cofactor II deficiency. Arch. Pathol. Lab. Med. 126 (2002) 1394-1400
54. Tollefsen D.M. Heparin cofactor II. Adv. Exp. Med. Biol. 425 (1997) 35-44
55. O'Keeffe D., et al. The heparin binding properties of heparin cofactor II suggest an antithrombin-like activation mechanism. J. Biol. Chem. 279 (2004) 50267-50273
56. Ragg H., et al. On the activation of human leuserpin-2, a thrombin inhibitor, by glycosaminoglycans. J. Biol. Chem. 265 (1990) 5211-5218
57. Van Deerlin V.M., and Tollefsen D.M. The N-terminal acidic domain of heparin cofactor II mediates the inhibition of α-thrombin in the presence of glycosaminoglycans. J. Biol. Chem. 266 (1991) 20223-20231
58. Baglin T.P., et al. Crystal structures of native and thrombin-complexed heparin cofactor II reveal a multistep allosteric mechanism. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 11079-11084
59. Verhamme I.M., et al. The preferred pathway of glycosaminoglycan-accelerated inactivation of thrombin by heparin cofactor II. J. Biol. Chem. 279 (2004) 9785-9795
60. Hoffman M., et al. Heparin cofactor II-proteinase reaction products exhibit neutrophil chemoattractant activity. Blood 73 (1989) 1682-1685
61. Mushunje A., et al. Heparin-induced substrate behavior of antithrombin Cambridge II. Blood 102 (2003) 4028-4034
62. Carrell R.W., et al. The conformational basis of thrombosis. Thromb. Haemost. 86 (2001) 14-22
63. Zhou A., et al. Formation of the antithrombin heterodimer In vivo and the onset of thrombosis. Blood 94 (1999) 3388-3396
64. Lomas D.A. Molecular mousetraps, α1-antitrypsin deficiency and the serpinopathies. Clin. Med. 5 (2005) 249-257
65. Lomas D.A., and Carrell R.W. Serpinopathies and the conformational dementias. Nat. Rev. Genet. 3 (2002) 759-768
66. Carrell R.W., and Lomas D.A. α1-Antitrypsin deficiency - a model for conformational diseases. N. Engl. J. Med. 346 (2002) 45-53
67. Davis R.L., et al. Familial dementia caused by polymerization of mutant neuroserpin. Nature 401 (1999) 376-379
68. Elliott P.R., et al. Topography of a 2.0 Å structure of α1-antitrypsin reveals targets for rational drug design to prevent conformational disease. Protein Sci. 9 (2000) 1274-1281
69. Horvath A.J., et al. The murine orthologue of human antichymotrypsin: a structural paradigm for clade A3 serpins. J. Biol. Chem. 280 (2005) 43168-43178
70. 1-antichymotrypsin indicates two-stage insertion of the reactive loop: implications for inhibitory function and conformational disease. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 67-72
71. Im H., et al. Interactions causing the kinetic trap in serpin protein folding. J. Biol. Chem. 277 (2002) 46347-46354
72. Brinkmeyer S., et al. Reformable intramolecular cross-linking of the N-terminal domain of heparin cofactor II: effects on enzyme inhibition. Eur. J. Biochem. 271 (2004) 4275-4283
73. Elliott P.R., et al. Inhibitory conformation of the reactive loop of α1-antitrypsin. Nat. Struct. Biol. 3 (1996) 676-681
74. Stark K.R., and James A.A. Isolation and characterization of the gene encoding a novel factor Xa-directed anticoagulant from the yellow fever mosquito, Aedes aegypti. J. Biol. Chem. 273 (1998) 20802-20809
75. Tesch L.D., et al. Specificity and reactive loop length requirements for crmA inhibition of serine proteases. Protein Sci. 14 (2005) 533-542
76. 1-antitrypsin to inhibit cathepsin proteases. Biochemistry 41 (2002) 4998-5004